Senate committee advances Susan Monarez to be Trump's CDC director
The committee voted 12-11 for advancing her nomination to the full Senate. The vote went along party lines, with Democrats in opposition.
Monarez, 50, is poised to become the first CDC director to pass through Senate confirmation following a 2023 law. She was named acting director in January and then tapped as the nominee in March after Trump abruptly withdrew his first choice, David Weldon.
She holds a doctorate in microbiology and immunology from the University of Wisconsin, and a postdoctoral researcher at Stanford University. Prior to the CDC, Monarez was largely known for her government roles in health technology and biosecurity.
The committee's action comes after months of turmoil with no leader at the helm of the Atlanta-based federal agency tasked with tracking diseases and responding to health threats.
The CDC has been hit by widespread staff cuts, resignations of key officials and heated controversy over longstanding CDC vaccine policies upended by Health Secretary Robert F. Kennedy Jr.
Last month, Monarez told senators that she values vaccines, public health interventions and rigorous scientific evidence, but she largely dodged questions about whether those positions put her at odds with Kennedy, a longtime vaccine skeptic who has criticized and sought to dismantle some of the agency's previous protocols and decisions.
'Unfortunately, Dr. Monarez — who has served as Trump's acting CDC director — has done nothing to stand in the way' of Kennedy's actions, Sen. Bernie Sanders, the Vermont independent, said Wednesday.
The CDC was created nearly 80 years ago to prevent the spread of malaria in the U.S. Its mission was later expanded, and it gradually became a global leader on infectious and chronic diseases and a go-to source of health information.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Several US executives to visit China this week: sources
By Laurie Chen BEIJING (Reuters) -A high-level delegation of American executives will travel to China this week to meet senior Chinese officials in a trip organised by the U.S.-China Business Council (USCBC), two sources with knowledge of the visit told Reuters on Monday. The visit coincides with the latest round of U.S.‑China trade negotiations in Sweden, where China's Vice Premier He Lifeng is meeting U.S. officials from July 27 to July 30 for a new round of economic and trade talks. The delegation will be led by FedEx Chief Executive Rajesh Subramaniam, the council's board chair, one of the sources briefed on the trip said. The South China Morning Post first reported the visit on Sunday, saying that executives from firms including Boeing would be part of the delegation. Reuters could not confirm other CEO members of the delegation or which Chinese officials they would meet. Boeing declined to comment on the trip and deferred to USCBC. The U.S. government was not involved in the organisation of the visit, one of the sources said. The trip comes as Beijing and Washington work towards a summit between the two countries' leaders later this year, probably around the time of the APEC forum in South Korea October 26 - November 1, sources previously told Reuters. USCBC did not respond immediately to a request for comment. The business lobby previously organised similar visits to China by American CEO delegations in 2023 and 2024. The 2024 trip, also led by Subramaniam, included meetings with He and Foreign Minister Wang Yi, where executives discussed issues including market access. China faces an August 12 deadline to reach a durable deal with the White House or risk higher U.S. tariffs. U.S. officials are likely to extend the deadline by another 90 days as both sides work towards a more comprehensive deal, sources previously told Reuters. An extension of that length would prevent further escalation and help create conditions for the potential meeting between Trump and Chinese President Xi Jinping. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
16 minutes ago
- Yahoo
Trump pauses export controls to bolster China trade deal, FT says
(Reuters) -The U.S. has paused curbs on tech exports to China to avoid disrupting trade talks with Beijing and support President Donald Trump's efforts to secure a meeting with President Xi Jinping this year, the Financial Times said on Monday. The industry and security bureau of the Commerce Department, which oversees export controls, has been told in recent months to avoid tough moves on China, the newspaper said, citing current and former officials. Reuters could not immediately verify the report. The White House and the department did not respond to Reuters' requests for comment outside business hours. Top U.S. and Chinese economic officials are set to resume talks in Stockholm on Monday to tackle longstanding economic disputes at the centre of a trade war between the world's top two economies. Tech giant Nvidia said this month it would resume sales of its H20 graphics processing units (GPU) to China, reversing an export curb the Trump administration imposed in April to keep advanced AI chips out of Chinese hands over national security concerns. The planned resumption was part of U.S. negotiations on rare earths and magnets, Commerce Secretary Howard Lutnick has said. The paper said 20 security experts and former officials, including former deputy US national security adviser Matt Pottinger, will write on Monday to Lutnick to voice concern, however. "This move represents a strategic misstep that endangers the United States' economic and military edge in artificial intelligence," they write in the letter, it added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
